IP Library Granted Patent US 9,398,979
Granted Patent B2
US 9,398,979 · App. 13/793,396 · Granted Jul 26, 2016

Dimensional compensator for use with a patient interface

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,398,979
App. No.
13/793,396
Granted
Jul 26, 2016
Kind
B2
Abstract

An apparatus and method are provided for performing ocular laser surgery using a patient interface having a posterior contact surface that may include surface irregularities that were generated during manufacturing of the patient interface. A beam delivery system having a focusing lens, scanning subsystem and adaptive optic (e.g. deformable mirror) is provided for guiding the surgical laser beam through the patient interface and to a desired focal spot location. An optical detector generates image data representing the posterior patient interface surface which is then processed by a computer system to identify surface irregularities by comparing the image data to a reference surface or axis. In particular, a surface irregularity can be identified as having a z-axis component; a tilt component and a surface profile component. Each irregularity component can be compensated separately by sending an adjustment signal to one of the beam delivery system components.

Claims (14)

1. An apparatus for directing a focal spot of a surgical laser beam to tissue in a treatment area of an eye during ocular surgery, with compensation for defects in laser beam position and quality caused by surface irregularities introduced during a manufacture of a patient interface, the apparatus comprising:

a patient interface having a posterior surface;

a beam delivery system including a scanning subsystem for guiding the surgical laser beam along a beam path through the patient interface and to a desired focal spot location in the treatment area;

an optical detector for creating image data including data representing at least a portion of the posterior surface of the patient interface; and

a computer system configured to receive image data from the optical detector and processing said image data to compare at least a portion of the posterior surface with a reference datum, wherein the reference datum is a computer model of a posterior surface of a patient interface having no surface irregularities, to calculate a z-axis deviation from the reference datum and a tilt deviation from the reference datum for the posterior surface of the patient interface due to irregularities of the posterior surface of the patient interface, and to generate an output signal to adjust the scanning subsystem in order to compensate for defects in laser beam position caused by the posterior surface irregularities of the patient interface.

2. An apparatus as recited in claim 1 wherein the optical detector creates image data representing the treatment area.

3. An apparatus as recited in claim 1 wherein the computer system processes the image data to identify an axis for the posterior surface and an anatomical axis for the eye as the reference datum and wherein the computer system compares the posterior surface axis to the anatomical axis to calculate patient interface tilt.

4. An apparatus as recited in claim 3 wherein the anatomical axis is the visual axis of the eye.

5. An apparatus as recited in claim 3 wherein the anatomical axis is the optical axis of the eye.

6. An apparatus as recited in claim 1 wherein the beam delivery system includes a focusing optic movable along a z-axis and wherein the computer system is adapted to process said image data to identify a z-axis coordinate where the beam passes through the posterior surface and compares the identified coordinate to a corresponding coordinate on the computer model of the patient interface surface having no surface irregularities to calculate a difference, Δz, the computer system adapted to output a signal to the beam delivery system indicative of the difference, Δz, to move the focusing optic and compensate for a z-axis deviation of the posterior surface irregularity.

7. An apparatus as recited in claim 1 wherein the optical detector is selected from the group of optical detectors consisting of an optical coherence tomography (OCT) detector, a confocal imaging detector, a Scheimpflug principle imaging detector, a two photon imaging detector and a second harmonic generation imaging detector.

8. An apparatus as recited in claim 1 wherein the posterior surface of the patient interface is sized and shaped to conform to the exterior surface of the cornea of the eye.

9. An apparatus as recited in claim 1 wherein the patent interface has an anterior surface and a posterior surface, and wherein each surface irregularity on the anterior surface and on the posterior surface is individually and separately compensated for.

10. An apparatus as recited in claim 1 wherein a same reference datum is used for calculating the z-axis deviation and the tilt deviation.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013
From: HOHLA, KRISTIAN; LOESEL, FRIEDER; MOSEDALE, GWILLEM; YOUSSEFI, GERHARD
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 030232/0383 →